[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333305-105":59,"doc-detail-333305-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-comprehensive-analysis-of-ribonucleotide-reductase-subunit-m2-for-carcinogenesis-in-pan-cancer","A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer","","Background Although evidence links ribonucleotide reductase subunit M2 (RRM2) to many cancers, pan-cancer characterization remains limited. This study investigates the carcinogenic potential of RRM2 across pan-cancer datasets. Methods UCSC Xena-derived data assessed RRM2 differential expression across cancer types, while clinical factors (age, race, sex, tumor stage, and status) were used to evaluate RRM2 associations. Molecular mechanisms were examined using genetic alterations, tumor mutational burden (TMB), microsatellite instability (MSI), pathway changes, and the immune microenvironment. Results RRM2 was highly expressed in most cancers and correlated with prognosis. RRM2 linked with infiltration of diverse immune and endothelial cells, immune checkpoints, TMB, MSI, and involvement of cell-cycle mechanisms. Conclusions The findings provide a comprehensive view of RRM2-driven carcinogenesis in diverse tumors.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-comprehensive-analysis-of-ribonucleotide-reductase-subunit-m2-for-carcinogenesis-in-pan-cancer/333305/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-comprehensive-analysis-of-ribonucleotide-reductase-subunit-m2-for-carcinogenesis-in-pan-cancer/333305.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of this pan-cancer study on RRM2?","Question",{"text":113,"@type":114},"To explore the potential role of ribonucleotide reductase subunit M2 (RRM2) in carcinogenesis across multiple cancer types using pan-cancer datasets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which data sources were used to analyze RRM2?",{"text":118,"@type":114},"RRM2 expression was evaluated using Oncomine (default parameters) and gene expression RNA-seq data from The Cancer Genome Atlas (TCGA) accessed via UCSC Xena.",{"name":120,"@type":111,"acceptedAnswer":121},"What main findings connect RRM2 to cancer development and outcomes?",{"text":122,"@type":114},"RRM2 showed high expression in most cancers, correlated with patient prognosis, and was associated with immune and endothelial cell infiltration, immune checkpoints, TMB, MSI, and cell-cycle-related mechanisms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},333305,1790807182,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","PLOS ONE  \nOPEN ACCESS  \nCitation: Wang Y, Chen R, Zhang J, Zeng P (2024) A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pancancer. PLoS ONE 19(4): e0299949 . [https://doi](https://doi). org/10 .1371/journal.pone.0299949  \nEditor: Arthur J. Lustig, Tulane University Health Sciences Center, UNITED STATES  \nReceived: October 21, 2023  \nAccepted: February 19, 2024  \nPublished: April 18, 2024  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here:  \n[https://doi.org/10.1371/journal.pone.0299949](https://doi.org/10.1371/journal.pone.0299949)  \n[Copyright:](Copyright:) © [2024 Wang](2024 Wang) et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the paper and its Supporting Information files.  \nFunding: This work was supported by the Jiangsu Provincial Special Program of Medical Science  \nRESEARCH ARTICLE  \nA comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer  \nYong Wang1, Rong Chen2, Jing Zhang2, Peng Zeng2 *  \n1 Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China, 2 Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China  \n* [zpeng701@163.com](zpeng701@163.com)  \nAbstract  \nBackground  \nAlthough there is evidence that ribonucleotide reductase subunit M2 (RRM2) is associated with numerous cancers, pan-cancer analysis has seldom been conducted. This study aimed to explore the potential carcinogenesis of RRM2 in pan-cancer using datasets from The Cancer Genome Atlas (TCGA) .  \nMethods  \nData from the UCSC Xena database were analyzed to investigate the differential expression of RRM2 across multiple cancer types. Clinical data such as age, race, sex, tumor stage, and status were acquired to analyze the influence of RRM2 on the clinical characteristics of the patients. The role of RRM2 in the onset and progression of multiple cancers has been examined in terms of genetic changes at the molecular level, including tumor mutational burden (TMB), microsatellite instability (MSI), biological pathway changes, and the immune microenvironment.  \nResults  \nRRM2 was highly expressed in most cancers, and there was an obvious correlation between RRM2 expression and patient prognosis. RRM2 expression is associated with the infiltration of diverse immune and endothelial cells, immune checkpoints, tumor mutational burden (TMB), and microsatellite instability (MSI) . Moreover, the cell cycle is involved in the functional mechanisms of RRM2.  \nConclusions  \nOur pan-cancer study provides a comprehensive understanding of the carcinogenesis of RRM2 in various tumors.  \n(BE2019750), National Natural Science Foundation of China (81827805), National Key Research and Development Program (2018YFA0704100, 2018YFA0704104), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (61821002), and Interventional Radiology Scientific Research Special Fund Project of Jiangsu Medical Association (SYH-3201140-0025 (2021020)) .  \nCompeting interests: The authors have declared that no competing interests exist.  \nIntroduction  \nGiven the complex causes of tumorigenesis such as genetic loss or alteration [ 1] and immune infiltration [2], it is crucial to perform pan-cancer analyses of genes that may have potential clinical value. Recently, with deeper research examining the initiation, development, and treatment of tumors, many t","cbCaisrzhTPqX3L3","https://ap.wps.com/l/cbCaisrzhTPqX3L3","pdf",5494785,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and methods\n## The expression of RRM2 in pan-cancer","[{\"question\":\"What was the purpose of this pan-cancer study on RRM2?\",\"answer\":\"To explore the potential role of ribonucleotide reductase subunit M2 (RRM2) in carcinogenesis across multiple cancer types using pan-cancer datasets.\"},{\"question\":\"Which data sources were used to analyze RRM2?\",\"answer\":\"RRM2 expression was evaluated using Oncomine (default parameters) and gene expression RNA-seq data from The Cancer Genome Atlas (TCGA) accessed via UCSC Xena.\"},{\"question\":\"What main findings connect RRM2 to cancer development and outcomes?\",\"answer\":\"RRM2 showed high expression in most cancers, correlated with patient prognosis, and was associated with immune and endothelial cell infiltration, immune checkpoints, TMB, MSI, and cell-cycle-related mechanisms.\"}]","A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer | PDF",1790001850,43]